NCT03175835 - Study to Evaluate the Drug Interaction Between CKD-519 and Rosuvastatin in Healthy Male Subjects | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 8, 2017

Primary Completion Date

June 19, 2017

Study Completion Date

June 19, 2017

Conditions

Dyslipidemias

Interventions

DRUG

Rosuvastatin 20 mg

Treatment A: Rosuvastatin 20 mg(20 mg X 1 tablet) for Day1\~Day5

DRUG

CKD-519 200 mg

Treatment B: CKD-519 200 mg(100 mg X 2 tablets) for Day9\~Day21

DRUG

Rosuvastatin 20 mg & CKD-519 200 mg

Treatment C: Rosuvastatin 20 mg(20 mg X 1 tablet), CKD-519 200 mg(100 mg X 2 tablets) for Day22\~Day26

Trial Locations (1)

Korea University Anam Hospital, Seoul